A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany
← catalyst calendarNCT06695897 · readout in 285 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
150estimated
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-02 | actual | When the study began enrolling |
| Primary completion | 2027-06-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-05-29 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Eosinophilic Esophagitis
Intervention
- Drug: Dupilumab
Primary outcomes
what the primary-completion date above is the date OFDescriptive statistical analysis of medical history characteristics
measured At baseline
Descriptive statistical analysis of socio-demographic characteristics
measured At baseline
Descriptive statistical analysis of disease characteristics
measured At baseline
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed